Intelligent Bio Solutions Inc.
NASDAQ: INBS · HEALTHCARE · MEDICAL DEVICES
Updated 2026-06-03
Intelligent Bio Solutions Inc. (INBS) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for INBS.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
INBS historical valuation range
Where current P/E sits in INBS's own 5Y range.
INBS intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
INBS valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 1.73x
Is INBS overvalued in 2026?
Intelligent Bio Solutions Inc. (INBS) currently trades at $4.11 per share with a market capitalization of $6,768,900.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 38/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
INBS currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 1.7x, the market is valuing the company primarily on its revenue rather than its earnings.
Our discounted cash flow model estimates INBS's intrinsic value at $4.26 per share, against the current market price of $4.11. This implies a premium to fair value of -23.24%. The current price sits well above what projected cash flows justify, implying investors are paying for growth that has not yet materialized.
Financial quality is a concern. The Piotroski F-Score of 2/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: INBS appears richly valued on our framework, with a Smart Value Score of 38/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is INBS overvalued?
INBS scores 38/100 on our Smart Value Score (Grade D), a weak overall profile. On valuation specifically, the DCF puts intrinsic value below the current price, so the stock is expensive on cash flow today. The score reflects growth and quality carrying it, not a cheap entry point.
What is INBS's fair value?
Our DCF model estimates INBS's intrinsic value at $4.26 per share, versus the current price of $4.11, a margin of safety of -23.24%. Fair value is the present value of the cash flows we project the business to produce, so a price above it means the market is paying up for growth the model does not yet assume.
What P/E ratio does INBS trade at?
INBS does not have a meaningful P/E right now, usually a sign of unprofitability or an earnings transition. For unprofitable growth names, price-to-sales is the more useful gauge.
Is INBS a buy based on valuation?
Our Smart Value rating for INBS is Sell, from a Smart Value Score of 38/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.
How does INBS's valuation compare to its history?
There is not enough historical valuation data yet for a confident percentile read on INBS.
What is INBS's Smart Value Score?
INBS's Smart Value Score is 38/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.